



The Drug Utilization Review (DUR) Board Reviewed  
the Following New Drugs/Classes on  
February 1, 2022

| <b>Therapeutic Class</b>       | <b>Drug Name</b>                        | <b>DURB Recommendation</b>       |
|--------------------------------|---|----------------------------------|
| <b>Antifungals, Oral</b>       |   |                                  |
|                                | <i>Brexafemme (Oral) Tablet</i>         | NP/PA                            |
| <b>Diuretics</b>               |   |                                  |
|                                | <i>Kerendia (Oral) Tablet</i>           | NP/PA                            |
| <b>Immunomodulators, Lupus</b> |   |                                  |
|                                | <i>Saphnelo (Intravenous) Injection</i> | NP/PA (for coverage on the PADL) |

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List